董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jane Hollingsworth | 女 | Director | 67 | 9.37万美元 | 2.27 | 2026-03-11 |
| Joshua S. Boger | 男 | Chair, Director | 74 | 未披露 | 未持股 | 2026-03-11 |
| John Alam | 男 | Chief Executive Officer and Director and President | 64 | 104.76万美元 | 161.25 | 2026-03-11 |
| Jeff Poulton | 男 | Director | 58 | 9.32万美元 | 5.12 | 2026-03-11 |
| Marwan Sabbagh | 男 | Director | 60 | 7.72万美元 | 2.44 | 2026-03-11 |
| Frank Zavrl | 男 | Director | 60 | 9.47万美元 | 38.77 | 2026-03-11 |
| David Quigley | 男 | Director | 58 | 8.14万美元 | 0.36 | 2026-03-11 |
| Sylvie Gregoire | 女 | Director | 64 | 7.32万美元 | 未持股 | 2026-03-11 |
| Joshua S. Boger | 男 | Chair, Director | 74 | 9.82万美元 | 107.89 | 2026-03-11 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Kelly Blackburn | 女 | Executive Vice President, Clinical Development | 62 | 65.25万美元 | 8.19 | 2026-03-11 |
| Mark De Rosch | 男 | Executive Vice President, Regulatory and Govt. Affairs and Program Mgmt | 62 | 未披露 | 未持股 | 2026-03-11 |
| William Elder | 男 | Chief Financial Officer and General Counsel | 43 | 68.63万美元 | 6.18 | 2026-03-11 |
| John Alam | 男 | Chief Executive Officer and Director and President | 64 | 104.76万美元 | 161.25 | 2026-03-11 |
| Marco Verwijs | -- | Executive Vice President, Technical Operations | 49 | 未披露 | 未持股 | 2026-03-11 |
| Matthew Winton | -- | Chief Commercial and Business Officer | 48 | 未披露 | 未持股 | 2026-03-11 |
董事简历
中英对照 | 中文 | 英文- Jane Hollingsworth
-
Jane Hollingsworth，2014年8月起，担任本公司董事。2013年10月至今，她一直担任Militia Hill Ventures LLC的管理合伙人、Immunome Inc.的执行董事长，前者是私营的生命科学行业加速器，后者是私营的肿瘤免疫治疗公司。2012年10月至2013年12月，她担任JHH Technologies LLC的总裁，这是提供医疗健康咨询服务的私营企业。2005年1月至2007年9月，她是 NuPathe Inc的首席执行官、联合创始人，这是专注于中枢神经系统疾病的上市制药企业。加入 NuPathe Inc之前，她曾是：上市制药企业Auxilium Pharmaceuticals的执行副总裁、联合创始人；IBAH Inc的副总裁、秘书、法律总顾问，这是一个上市的临床研究机构，在1998年被出售给Omnicare Inc.职业生涯之初，她是律师事务所Montgomery, McCracken, Walker & Rhoads的一名商业诉讼律师，后来曾担任美国特拉华州地区法院Honorable Jane R. Roth的法务助理。她在Gettysburg College获得西班牙语学士学位，在Villanova University获得法律博士学位。
Jane Hollingsworth,has served as a director since September 2020. Ms. Hollingsworth previously served as Chair of Diffusion's board of directors from June 2021 to August 2023. She currently serves as the founding Managing Partner of Militia Hill Ventures, an organization that creates, builds, and invests in life sciences companies, a role she has held since 2013. While at Militia Hill, Jane co-founded and currently serves as Executive Chair of Eliksa Therapeutics, a regenerative medicine company, co-founded and served as Executive Chair of Spirovant Sciences, a gene therapy company sold to Sumitomo Dainippon Pharma, and served as Executive Chair and CEO of Immunome Inc. (NASDAQ: IMNM), a cancer immunotherapy company. Prior to founding Militia Hill, Ms. Hollingsworth co-founded and served as Chief Executive Officer of NuPathe, Inc., a neuroscience focused biopharmaceutical company. She also co-founded and served as EVP of Auxilium Pharmaceuticals, a urology and rare disease focused biopharmaceutical company. Ms. Hollingsworth also currently serves on the boards of the life science companies Afimmune Ltd. and Ribonova, and various industry and community organizations, including the University City Science Center, the Kimmel Center for the Performing Arts and Breastcancer.Org. Ms. Hollingsworth received her B.A. from Gettysburg College and her J.D. from Villanova University. - Jane Hollingsworth，2014年8月起，担任本公司董事。2013年10月至今，她一直担任Militia Hill Ventures LLC的管理合伙人、Immunome Inc.的执行董事长，前者是私营的生命科学行业加速器，后者是私营的肿瘤免疫治疗公司。2012年10月至2013年12月，她担任JHH Technologies LLC的总裁，这是提供医疗健康咨询服务的私营企业。2005年1月至2007年9月，她是 NuPathe Inc的首席执行官、联合创始人，这是专注于中枢神经系统疾病的上市制药企业。加入 NuPathe Inc之前，她曾是：上市制药企业Auxilium Pharmaceuticals的执行副总裁、联合创始人；IBAH Inc的副总裁、秘书、法律总顾问，这是一个上市的临床研究机构，在1998年被出售给Omnicare Inc.职业生涯之初，她是律师事务所Montgomery, McCracken, Walker & Rhoads的一名商业诉讼律师，后来曾担任美国特拉华州地区法院Honorable Jane R. Roth的法务助理。她在Gettysburg College获得西班牙语学士学位，在Villanova University获得法律博士学位。
- Jane Hollingsworth,has served as a director since September 2020. Ms. Hollingsworth previously served as Chair of Diffusion's board of directors from June 2021 to August 2023. She currently serves as the founding Managing Partner of Militia Hill Ventures, an organization that creates, builds, and invests in life sciences companies, a role she has held since 2013. While at Militia Hill, Jane co-founded and currently serves as Executive Chair of Eliksa Therapeutics, a regenerative medicine company, co-founded and served as Executive Chair of Spirovant Sciences, a gene therapy company sold to Sumitomo Dainippon Pharma, and served as Executive Chair and CEO of Immunome Inc. (NASDAQ: IMNM), a cancer immunotherapy company. Prior to founding Militia Hill, Ms. Hollingsworth co-founded and served as Chief Executive Officer of NuPathe, Inc., a neuroscience focused biopharmaceutical company. She also co-founded and served as EVP of Auxilium Pharmaceuticals, a urology and rare disease focused biopharmaceutical company. Ms. Hollingsworth also currently serves on the boards of the life science companies Afimmune Ltd. and Ribonova, and various industry and community organizations, including the University City Science Center, the Kimmel Center for the Performing Arts and Breastcancer.Org. Ms. Hollingsworth received her B.A. from Gettysburg College and her J.D. from Villanova University.
- Joshua S. Boger
-
Joshua S. Boger是美国公民，曾任联合国副秘书长。
Joshua S. Boger,has served as a director and the Chair of the Board since February 2024. Dr. Boger is the founder of Vertex Pharmaceuticals (NASDAQ: VRTX) and served as its Chief Executive Officer from 1992 to May 2009, as chairman of its board of directors from 1997 to 2006, and as a director from 1989 until his retirement from the Vertex Pharmaceuticals board of directors in 2017. Prior to founding Vertex Pharmaceuticals in 1989, Dr. Boger held the position of Senior Director of Basic Chemistry at Merck Sharp & Dohme Research Laboratories in Rahway, New Jersey, where he headed both the Department of Medicinal Chemistry of Immunology & Inflammation and the Department of Biophysical Chemistry. Dr. Boger currently serves as chairman of the board of directors of Alkeus Pharmaceuticals, Inc., a privately-held biotechnology company focused on treating degenerative eye diseases, and is an Investor Director of a UK-based, privately-held medical device company, mOm Incubators Ltd. Dr. Boger holds a B.A. in chemistry and philosophy from Wesleyan University and M.S. and Ph.D. degrees in chemistry from Harvard University. His postdoctoral research in molecular recognition was performed in the laboratories of the Nobel-prize winning chemist, Jean-Marie Lehn in Strasbourg, France. He is the author of over 50 scientific publications and holds 32 issued U.S. patents in pharmaceutical discovery and development. - Joshua S. Boger是美国公民，曾任联合国副秘书长。
- Joshua S. Boger,has served as a director and the Chair of the Board since February 2024. Dr. Boger is the founder of Vertex Pharmaceuticals (NASDAQ: VRTX) and served as its Chief Executive Officer from 1992 to May 2009, as chairman of its board of directors from 1997 to 2006, and as a director from 1989 until his retirement from the Vertex Pharmaceuticals board of directors in 2017. Prior to founding Vertex Pharmaceuticals in 1989, Dr. Boger held the position of Senior Director of Basic Chemistry at Merck Sharp & Dohme Research Laboratories in Rahway, New Jersey, where he headed both the Department of Medicinal Chemistry of Immunology & Inflammation and the Department of Biophysical Chemistry. Dr. Boger currently serves as chairman of the board of directors of Alkeus Pharmaceuticals, Inc., a privately-held biotechnology company focused on treating degenerative eye diseases, and is an Investor Director of a UK-based, privately-held medical device company, mOm Incubators Ltd. Dr. Boger holds a B.A. in chemistry and philosophy from Wesleyan University and M.S. and Ph.D. degrees in chemistry from Harvard University. His postdoctoral research in molecular recognition was performed in the laboratories of the Nobel-prize winning chemist, Jean-Marie Lehn in Strasbourg, France. He is the author of over 50 scientific publications and holds 32 issued U.S. patents in pharmaceutical discovery and development.
- John Alam
-
John Alam，自2023年8月起担任总裁兼首席执行官和董事。Alam博士是EIP的联合创始人，曾于2018年4月至2023年8月担任EIP总裁兼首席执行官，并担任EIP董事会成员。在此之前，Alam博士自2010年成立以来一直担任EIP的前身实体EIP Pharma，LLC的管理成员。2011年1月至2014年8月，Alam博士在全球制药公司赛诺菲 S.A.（NASDAQ：SNY）担任老龄化疾病治疗领域负责人。从1997年到2008年，他在福泰制药（纳斯达克股票代码：VRTX）担任越来越重要的职务，最近担任首席医疗官和药物开发执行副总裁。1991年至1997年，Alam博士曾在Biogen Inc.（纳斯达克股票代码：BIIB）工作，在那里他领导了Avonex的临床开发，这是一种治疗多发性硬化症的药物。从2014年到2022年，Alam博士担任老龄化研究联盟的董事会成员，该联盟是一个非营利组织，致力于促进创新，以满足美国老年人的医疗保健需求。Alam博士获得了麻省理工学院化学工程学的S.B.和西北大学医学院的医学博士学位。Alam博士在布莱根妇女医院完成了内科住院医师实习，并在Dana-Farber癌症研究所完成了博士后奖学金。
John Alam,has served as President and Chief Executive Officer and as a director since August 2023. Dr. Alam was EIP's co-founder and served as EIP's President and Chief Executive Officer and as a member of EIP's board of directors from April 2018 to August 2023. Prior to that, Dr. Alam served as a managing member of EIP Pharma, LLC, EIP's predecessor entity, from its inception in 2010. From January 2011 to August 2014, Dr. Alam served as therapeutic area head for diseases of aging at Sanofi S.A. (NASDAQ: SNY), a global pharmaceutical company. From 1997 until 2008, he held positions of increasing responsibility at Vertex Pharmaceuticals (NASDAQ: VRTX), most recently as Chief Medical Officer and Executive Vice President, Medicines Development. From 1991 to 1997, Dr. Alam worked at Biogen Inc. (NASDAQ: BIIB), where he led the clinical development of Avonex, a drug that treats multiple sclerosis. From 2014 to 2022, Dr. Alam served as a member of the board of directors of the Alliance for Aging Research, a non-profit organization dedicated to promoting innovation to address the healthcare needs of older Americans. Dr. Alam received an S.B. in chemical engineering from the Massachusetts Institute of Technology and a M.D. from Northwestern University School of Medicine. Dr. Alam completed an internal medicine residency at Brigham and Women's Hospital and a post-doctoral fellowship at Dana-Farber Cancer Institute. - John Alam，自2023年8月起担任总裁兼首席执行官和董事。Alam博士是EIP的联合创始人，曾于2018年4月至2023年8月担任EIP总裁兼首席执行官，并担任EIP董事会成员。在此之前，Alam博士自2010年成立以来一直担任EIP的前身实体EIP Pharma，LLC的管理成员。2011年1月至2014年8月，Alam博士在全球制药公司赛诺菲 S.A.（NASDAQ：SNY）担任老龄化疾病治疗领域负责人。从1997年到2008年，他在福泰制药（纳斯达克股票代码：VRTX）担任越来越重要的职务，最近担任首席医疗官和药物开发执行副总裁。1991年至1997年，Alam博士曾在Biogen Inc.（纳斯达克股票代码：BIIB）工作，在那里他领导了Avonex的临床开发，这是一种治疗多发性硬化症的药物。从2014年到2022年，Alam博士担任老龄化研究联盟的董事会成员，该联盟是一个非营利组织，致力于促进创新，以满足美国老年人的医疗保健需求。Alam博士获得了麻省理工学院化学工程学的S.B.和西北大学医学院的医学博士学位。Alam博士在布莱根妇女医院完成了内科住院医师实习，并在Dana-Farber癌症研究所完成了博士后奖学金。
- John Alam,has served as President and Chief Executive Officer and as a director since August 2023. Dr. Alam was EIP's co-founder and served as EIP's President and Chief Executive Officer and as a member of EIP's board of directors from April 2018 to August 2023. Prior to that, Dr. Alam served as a managing member of EIP Pharma, LLC, EIP's predecessor entity, from its inception in 2010. From January 2011 to August 2014, Dr. Alam served as therapeutic area head for diseases of aging at Sanofi S.A. (NASDAQ: SNY), a global pharmaceutical company. From 1997 until 2008, he held positions of increasing responsibility at Vertex Pharmaceuticals (NASDAQ: VRTX), most recently as Chief Medical Officer and Executive Vice President, Medicines Development. From 1991 to 1997, Dr. Alam worked at Biogen Inc. (NASDAQ: BIIB), where he led the clinical development of Avonex, a drug that treats multiple sclerosis. From 2014 to 2022, Dr. Alam served as a member of the board of directors of the Alliance for Aging Research, a non-profit organization dedicated to promoting innovation to address the healthcare needs of older Americans. Dr. Alam received an S.B. in chemical engineering from the Massachusetts Institute of Technology and a M.D. from Northwestern University School of Medicine. Dr. Alam completed an internal medicine residency at Brigham and Women's Hospital and a post-doctoral fellowship at Dana-Farber Cancer Institute.
- Jeff Poulton
-
Jeff Poulton，自2023年8月起担任董事。Poulton先生此前曾于2018年4月至2023年8月在EIP董事会任职。自2019年7月起，Poulton先生在Alnylam Pharmaceuticals, Inc.（纳斯达克股票代码：ALNY）担任首席财务官，该公司是一家总部位于马萨诸塞州剑桥市的全球性生物制药公司。2018年1月至2019年4月，Poulton先生在植物微生物组公司Indigo Agriculture担任首席财务官。从1998年9月至2017年12月，Poulton先生在生物技术公司Shire plc担任了各种职责不断增加的职务，最终于2014年7月至2017年12月担任首席财务官，并于2015年1月至2017年12月担任Shire执行委员会和董事会成员。在Shire任职期间，Poulton先生还领导了Shire的罕见病美国/亚太地区和拉丁美洲的商业运营，以及Shire的罕见病业务部门。在Shire任职之前，Poulton先生领导了天然气和电力公用事业行业以及材料制造行业的公司融资和业务发展计划，曾在Cinergy Corporation和PPG工业，Inc.担任财务领导职务。Poulton先生还曾在“皮奥里亚”号航空母舰上担任美国海军特命军官。Poulton先生拥有杜克大学经济学学士学位和印第安纳大学凯利商学院金融硕士学位。
Jeff Poulton,has served as a director since August 2023. Mr. Poulton previously served on EIP's board of directors from April 2018 to August 2023. Since July 2019, Mr. Poulton has served as Chief Financial Officer at Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), a global biopharmaceutical company based in Cambridge, Massachusetts. From January 2018 to April 2019, Mr. Poulton served as chief financial officer at Indigo Agriculture, a plant microbiome company. From September 1998 to December 2017, Mr. Poulton held various roles of increasing responsibility at Shire plc, a biotechnology company, culminating in his service as chief financial officer from July 2014 to December 2017 and a member of Shire's executive committee and board of directors from January 2015 to December 2017. During his tenure at Shire, Mr. Poulton also led Shire's rare disease US/APAC and LATAM commercial operations, as well as Shire's rare disease business unit. Prior to his tenure at Shire, Mr. Poulton led corporate finance and business development initiatives in both the gas and electric utilities industry and the materials manufacturing sector, serving in financial leadership positions at Cinergy Corporation and PPG Industries, Inc. Mr. Poulton also served as a U.S. Navy Commissioned Officer aboard the USS Peoria. Mr. Poulton holds a B.A. in Economics from Duke University and an M.B.A. in Finance from the Kelly School of Business at Indiana University. - Jeff Poulton，自2023年8月起担任董事。Poulton先生此前曾于2018年4月至2023年8月在EIP董事会任职。自2019年7月起，Poulton先生在Alnylam Pharmaceuticals, Inc.（纳斯达克股票代码：ALNY）担任首席财务官，该公司是一家总部位于马萨诸塞州剑桥市的全球性生物制药公司。2018年1月至2019年4月，Poulton先生在植物微生物组公司Indigo Agriculture担任首席财务官。从1998年9月至2017年12月，Poulton先生在生物技术公司Shire plc担任了各种职责不断增加的职务，最终于2014年7月至2017年12月担任首席财务官，并于2015年1月至2017年12月担任Shire执行委员会和董事会成员。在Shire任职期间，Poulton先生还领导了Shire的罕见病美国/亚太地区和拉丁美洲的商业运营，以及Shire的罕见病业务部门。在Shire任职之前，Poulton先生领导了天然气和电力公用事业行业以及材料制造行业的公司融资和业务发展计划，曾在Cinergy Corporation和PPG工业，Inc.担任财务领导职务。Poulton先生还曾在“皮奥里亚”号航空母舰上担任美国海军特命军官。Poulton先生拥有杜克大学经济学学士学位和印第安纳大学凯利商学院金融硕士学位。
- Jeff Poulton,has served as a director since August 2023. Mr. Poulton previously served on EIP's board of directors from April 2018 to August 2023. Since July 2019, Mr. Poulton has served as Chief Financial Officer at Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), a global biopharmaceutical company based in Cambridge, Massachusetts. From January 2018 to April 2019, Mr. Poulton served as chief financial officer at Indigo Agriculture, a plant microbiome company. From September 1998 to December 2017, Mr. Poulton held various roles of increasing responsibility at Shire plc, a biotechnology company, culminating in his service as chief financial officer from July 2014 to December 2017 and a member of Shire's executive committee and board of directors from January 2015 to December 2017. During his tenure at Shire, Mr. Poulton also led Shire's rare disease US/APAC and LATAM commercial operations, as well as Shire's rare disease business unit. Prior to his tenure at Shire, Mr. Poulton led corporate finance and business development initiatives in both the gas and electric utilities industry and the materials manufacturing sector, serving in financial leadership positions at Cinergy Corporation and PPG Industries, Inc. Mr. Poulton also served as a U.S. Navy Commissioned Officer aboard the USS Peoria. Mr. Poulton holds a B.A. in Economics from Duke University and an M.B.A. in Finance from the Kelly School of Business at Indiana University.
- Marwan Sabbagh
-
Marwan Sabbagh，自2023年8月起担任董事。Sabbagh博士此前曾于2021年11月至2023年8月担任EIP董事会成员。自2021年10月以来，Sabbagh博士一直担任巴罗神经学研究所神经病学系教授，最近成为研究副主席。Sabbagh博士获得了美国精神病学和神经病学委员会的神经病学委员会认证，并且是美国神经病学学会的研究员。此前，从2018年5月到2021年10月，Sabbagh博士是克利夫兰诊所Lou Ruvo脑健康中心的神经科医生和主任。在任职于克利夫兰诊所之前，Sabbagh博士于2000年至2015年期间担任邦纳太阳健康研究所的主任和神经科医生。Sabbagh博士于2022年3月至2022年9月期间在Quince Therapeutics，Inc.（f/k/a/Cortexyme, Inc.）（NASDAQ：QNCX）的董事会任职。Sabbagh博士在亚利桑那大学医学院获得医学学位，在加州大学伯克利分校获得本科学位。他在贝勒医学院完成了神经病学住院医师实习，并在加州大学圣地亚哥分校医学院完成了老年神经病学和痴呆症研究金。
Marwan Sabbagh,has served as a director since August 2023. Dr. Sabbagh previously served as a member of EIP's board of directors from November 2021 to August 2023. Since October 2021, Dr. Sabbagh has served as a professor in the Department of Neurology, and recently became Vice Chairman for Research, at the Barrow Neurological Institute. Dr. Sabbagh is board certified in neurology by the American Board of Psychiatry and Neurology and is a fellow of the American Academy of Neurology. Previously, from May 2018 to October 2021, Dr. Sabbagh was a neurologist and director at the Cleveland Clinic Lou Ruvo Center for Brain Health. Prior to his time at the Cleveland Clinic, Dr. Sabbagh was a director and neurologist at the Banner Sun Health Research Institute from 2000 to 2015. Dr. Sabbagh served on the board of directors of Quince Therapeutics, Inc. (f/k/a/ Cortexyme, Inc.) (NASDAQ: QNCX) from March 2022 to September 2022. Dr. Sabbagh earned his medical degree from the University of Arizona College of Medicine and his undergraduate degree from the University of California Berkeley. He completed his neurology residency at Baylor College of Medicine and a geriatric neurology and dementia fellowship at the University of California San Diego School of Medicine. - Marwan Sabbagh，自2023年8月起担任董事。Sabbagh博士此前曾于2021年11月至2023年8月担任EIP董事会成员。自2021年10月以来，Sabbagh博士一直担任巴罗神经学研究所神经病学系教授，最近成为研究副主席。Sabbagh博士获得了美国精神病学和神经病学委员会的神经病学委员会认证，并且是美国神经病学学会的研究员。此前，从2018年5月到2021年10月，Sabbagh博士是克利夫兰诊所Lou Ruvo脑健康中心的神经科医生和主任。在任职于克利夫兰诊所之前，Sabbagh博士于2000年至2015年期间担任邦纳太阳健康研究所的主任和神经科医生。Sabbagh博士于2022年3月至2022年9月期间在Quince Therapeutics，Inc.（f/k/a/Cortexyme, Inc.）（NASDAQ：QNCX）的董事会任职。Sabbagh博士在亚利桑那大学医学院获得医学学位，在加州大学伯克利分校获得本科学位。他在贝勒医学院完成了神经病学住院医师实习，并在加州大学圣地亚哥分校医学院完成了老年神经病学和痴呆症研究金。
- Marwan Sabbagh,has served as a director since August 2023. Dr. Sabbagh previously served as a member of EIP's board of directors from November 2021 to August 2023. Since October 2021, Dr. Sabbagh has served as a professor in the Department of Neurology, and recently became Vice Chairman for Research, at the Barrow Neurological Institute. Dr. Sabbagh is board certified in neurology by the American Board of Psychiatry and Neurology and is a fellow of the American Academy of Neurology. Previously, from May 2018 to October 2021, Dr. Sabbagh was a neurologist and director at the Cleveland Clinic Lou Ruvo Center for Brain Health. Prior to his time at the Cleveland Clinic, Dr. Sabbagh was a director and neurologist at the Banner Sun Health Research Institute from 2000 to 2015. Dr. Sabbagh served on the board of directors of Quince Therapeutics, Inc. (f/k/a/ Cortexyme, Inc.) (NASDAQ: QNCX) from March 2022 to September 2022. Dr. Sabbagh earned his medical degree from the University of Arizona College of Medicine and his undergraduate degree from the University of California Berkeley. He completed his neurology residency at Baylor College of Medicine and a geriatric neurology and dementia fellowship at the University of California San Diego School of Medicine.
- Frank Zavrl
-
Frank Zavrl，自2023年8月起担任董事。Zavrl先生此前曾于2018年4月至2023年8月担任EIP董事会成员。2017年9月至2018年3月，Zavrl先生担任EIP Pharma，LLC董事会成员。在此之前，Zavrl先生于2015年9月至2020年7月期间担任Puma Biotechnology, Inc.（NASDAQ：PBYI）的董事会成员，该公司是一家上市公司，专注于癌症的治疗。从2002年到2011年，Zavrl先生担任资产管理公司Adage Capital Management，L.P.的合伙人，Zavrl先生专门从事生物技术投资。1999年至2002年，Zavrl先生在医疗保健投资公司Merlin BioMed Group担任投资组合经理。在此之前，Zavrl先生于1998年至1999年担任Scudder Kemper Investments Inc.的分析师，专注于生物技术投资。Zavrl先生获得了加州大学伯克利分校的生物化学学士学位和达特茅斯学院塔克商学院的工商管理硕士学位。
Frank Zavrl,has served as a director since August 2023. Mr. Zavrl previously served as a member of EIP's board of directors from April 2018 to August 2023. From September 2017 to March 2018, Mr. Zavrl served as a member of the board of directors of EIP Pharma, LLC. Prior to that, Mr. Zavrl served on the board of directors of Puma Biotechnology, Inc. (NASDAQ: PBYI), a publicly-traded company focused on the treatment of cancer, from September 2015 to July 2020. From 2002 to 2011, Mr. Zavrl served as a Partner at Adage Capital Management, L.P., an asset management company, where Mr. Zavrl specialized in biotechnology investments. From 1999 to 2002, Mr. Zavrl served as a Portfolio Manager at Merlin BioMed Group, a healthcare investment firm. Prior to that, Mr. Zavrl served from 1998 to 1999 as an analyst at Scudder Kemper Investments Inc., focusing on biotechnology investments. Mr. Zavrl received a B.S. in Biochemistry from the University of California, Berkeley and an M.B.A. from the Tuck School of Business at Dartmouth College. - Frank Zavrl，自2023年8月起担任董事。Zavrl先生此前曾于2018年4月至2023年8月担任EIP董事会成员。2017年9月至2018年3月，Zavrl先生担任EIP Pharma，LLC董事会成员。在此之前，Zavrl先生于2015年9月至2020年7月期间担任Puma Biotechnology, Inc.（NASDAQ：PBYI）的董事会成员，该公司是一家上市公司，专注于癌症的治疗。从2002年到2011年，Zavrl先生担任资产管理公司Adage Capital Management，L.P.的合伙人，Zavrl先生专门从事生物技术投资。1999年至2002年，Zavrl先生在医疗保健投资公司Merlin BioMed Group担任投资组合经理。在此之前，Zavrl先生于1998年至1999年担任Scudder Kemper Investments Inc.的分析师，专注于生物技术投资。Zavrl先生获得了加州大学伯克利分校的生物化学学士学位和达特茅斯学院塔克商学院的工商管理硕士学位。
- Frank Zavrl,has served as a director since August 2023. Mr. Zavrl previously served as a member of EIP's board of directors from April 2018 to August 2023. From September 2017 to March 2018, Mr. Zavrl served as a member of the board of directors of EIP Pharma, LLC. Prior to that, Mr. Zavrl served on the board of directors of Puma Biotechnology, Inc. (NASDAQ: PBYI), a publicly-traded company focused on the treatment of cancer, from September 2015 to July 2020. From 2002 to 2011, Mr. Zavrl served as a Partner at Adage Capital Management, L.P., an asset management company, where Mr. Zavrl specialized in biotechnology investments. From 1999 to 2002, Mr. Zavrl served as a Portfolio Manager at Merlin BioMed Group, a healthcare investment firm. Prior to that, Mr. Zavrl served from 1998 to 1999 as an analyst at Scudder Kemper Investments Inc., focusing on biotechnology investments. Mr. Zavrl received a B.S. in Biochemistry from the University of California, Berkeley and an M.B.A. from the Tuck School of Business at Dartmouth College.
- David Quigley
-
大卫·奎格利，曾在全球咨询公司麦肯锡公司（“麦肯锡”）任职超过25年，包括2010年至2025年担任高级合伙人。作为麦肯锡的高级合伙人，奎格利先生有时担任各种领导职务，包括私人资本（私募股权）全球主管、生命科学北美主管和生命科学商业全球主管。他还曾于2010年至2017年在哥伦比亚大学梅尔曼公共卫生学院担任生命科学的客座讲师。Quigley先生拥有都柏林大学学院的学士学位、贝尔法斯特女王大学的理学硕士学位和欧洲工商管理学院的工商管理硕士学位。
David Quigley,served at the global consulting firm McKinsey & Company ("McKinsey") for more than 25 years, including as Senior Partner from 2010 to 2025. While a Senior Partner at McKinsey, Mr. Quigley at times held various leadership roles including Global Head of Private Capital (Private Equity), North America Head of Life Sciences, and Global Lead of Life Sciences Commercial. He also served as a guest lecturer on Life Sciences at Columbia University's Mailman School of Public Health from 2010 to 2017. Mr. Quigley holds a B.A. from University College Dublin, an M.Sc. from Queen's University Belfast, and an M.B.A. from INSEAD. - 大卫·奎格利，曾在全球咨询公司麦肯锡公司（“麦肯锡”）任职超过25年，包括2010年至2025年担任高级合伙人。作为麦肯锡的高级合伙人，奎格利先生有时担任各种领导职务，包括私人资本（私募股权）全球主管、生命科学北美主管和生命科学商业全球主管。他还曾于2010年至2017年在哥伦比亚大学梅尔曼公共卫生学院担任生命科学的客座讲师。Quigley先生拥有都柏林大学学院的学士学位、贝尔法斯特女王大学的理学硕士学位和欧洲工商管理学院的工商管理硕士学位。
- David Quigley,served at the global consulting firm McKinsey & Company ("McKinsey") for more than 25 years, including as Senior Partner from 2010 to 2025. While a Senior Partner at McKinsey, Mr. Quigley at times held various leadership roles including Global Head of Private Capital (Private Equity), North America Head of Life Sciences, and Global Lead of Life Sciences Commercial. He also served as a guest lecturer on Life Sciences at Columbia University's Mailman School of Public Health from 2010 to 2017. Mr. Quigley holds a B.A. from University College Dublin, an M.Sc. from Queen's University Belfast, and an M.B.A. from INSEAD.
- Sylvie Gregoire
-
Sylvie Gregoire是EIP Pharma，Inc.的联合创始人，自2018年起担任执行主席，EIP Pharma，Inc.是一家专注于中枢神经系统疾病的私营治疗公司。Gregoire博士曾于2007年至2013年担任上市生物制药公司Shire plc的人类基因治疗部门总裁，2005年至2008年，她担任IDM Pharma，Inc.的董事，IDM Pharma，Inc.是一家上市生物技术公司，现在作为武田制药的子公司运营，包括在2006年至2007年担任其执行主席。此前，Gregoire博士曾担任私营生物技术公司GlycoFi，Inc.的总裁、首席执行官和董事会执行成员。在此之前，Gregoire博士曾受雇于渤健公司和默沙东公司的几个关键运营和监管事务职位。Gregoire博士目前在Novo Nordisk A/S以及一家私营生物技术公司的董事会任职，曾任职于Vifor Pharma Ltd.的董事会。Gregoire博士拥有拉瓦尔大学的药学学位和纽约州立大学布法罗分校的博士学位。
Sylvie Gregoire,was a co-founder, and since 2018 has served as Executive Chair, of EIP Pharma, Inc., a privately held therapeutics company focused on central nervous system disorders. Dr. Gregoire previously served as President of the Human Genetic Therapies division of Shire plc, a public biopharmaceutical company, from 2007 to 2013, and from 2005 to 2008 she served as a director of IDM Pharma, Inc., a public biotechnology company that now operates as a subsidiary of Takeda Pharmaceuticals, including serving as its Executive Chair from 2006 to 2007. Previously, Dr. Gregoire served as President, Chief Executive Officer and Executive Member of the board of directors of GlycoFi, Inc., a private biotechnology company. Prior to that, Dr. Gregoire was employed in several key operating and regulatory affairs positions at Biogen, Inc. and Merck & Co. Dr. Gregoire currently serves on the board of Novo Nordisk A/S, as well as a privately held biotechnology company, and formerly served on the board of Vifor Pharma Ltd. Dr. Gregoire holds a Pharmacy degree from Laval University and a doctoral degree from the State University of New York at Buffalo. - Sylvie Gregoire是EIP Pharma，Inc.的联合创始人，自2018年起担任执行主席，EIP Pharma，Inc.是一家专注于中枢神经系统疾病的私营治疗公司。Gregoire博士曾于2007年至2013年担任上市生物制药公司Shire plc的人类基因治疗部门总裁，2005年至2008年，她担任IDM Pharma，Inc.的董事，IDM Pharma，Inc.是一家上市生物技术公司，现在作为武田制药的子公司运营，包括在2006年至2007年担任其执行主席。此前，Gregoire博士曾担任私营生物技术公司GlycoFi，Inc.的总裁、首席执行官和董事会执行成员。在此之前，Gregoire博士曾受雇于渤健公司和默沙东公司的几个关键运营和监管事务职位。Gregoire博士目前在Novo Nordisk A/S以及一家私营生物技术公司的董事会任职，曾任职于Vifor Pharma Ltd.的董事会。Gregoire博士拥有拉瓦尔大学的药学学位和纽约州立大学布法罗分校的博士学位。
- Sylvie Gregoire,was a co-founder, and since 2018 has served as Executive Chair, of EIP Pharma, Inc., a privately held therapeutics company focused on central nervous system disorders. Dr. Gregoire previously served as President of the Human Genetic Therapies division of Shire plc, a public biopharmaceutical company, from 2007 to 2013, and from 2005 to 2008 she served as a director of IDM Pharma, Inc., a public biotechnology company that now operates as a subsidiary of Takeda Pharmaceuticals, including serving as its Executive Chair from 2006 to 2007. Previously, Dr. Gregoire served as President, Chief Executive Officer and Executive Member of the board of directors of GlycoFi, Inc., a private biotechnology company. Prior to that, Dr. Gregoire was employed in several key operating and regulatory affairs positions at Biogen, Inc. and Merck & Co. Dr. Gregoire currently serves on the board of Novo Nordisk A/S, as well as a privately held biotechnology company, and formerly served on the board of Vifor Pharma Ltd. Dr. Gregoire holds a Pharmacy degree from Laval University and a doctoral degree from the State University of New York at Buffalo.
- Joshua S. Boger
-
Joshua S. Boger，是Vertex的创始人；1992年至2009年5月，担任本公司的首席执行官；1997年至2006年5月，担任董事长；自本公司成立之时至2000年12月，以及2005年至2009年2月，担任总裁；1989年至1992年5月，担任首席科学官。1989年创办Vertex之前，他在新泽西州Rahway的Merck Sharp & Dohme Research Laboratories 担任基础化学高级总监，领导免疫学和炎症药物化学部、生物物理化学部。他在Wesleyan University 获得化学与哲学学士学位，在Harvard University获得化学硕士、博士学位。
Joshua S. Boger is the founder of Vertex and has been a director since inception in 1989. He was Chief Executive Officer from 1992 through May 2009. He was Chairman of Board of Directors from 1997 until May 2006 and President from inception until December 2000 and from 2005 through February 2009. He was Chief Scientific Officer from 1989 until May 1992. Prior to founding Vertex in 1989 Dr. Boger held the position of Senior Director of Basic Chemistry at Merck Sharp & Dohme Research Laboratories in Rahway, New Jersey, where he headed both the Department of Medicinal Chemistry of Immunology & Inflammation and the Department of Biophysical Chemistry. Dr. Boger holds a B.A. in chemistry and philosophy from Wesleyan University and M.S. and Ph.D. degrees in chemistry from Harvard University. - Joshua S. Boger，是Vertex的创始人；1992年至2009年5月，担任本公司的首席执行官；1997年至2006年5月，担任董事长；自本公司成立之时至2000年12月，以及2005年至2009年2月，担任总裁；1989年至1992年5月，担任首席科学官。1989年创办Vertex之前，他在新泽西州Rahway的Merck Sharp & Dohme Research Laboratories 担任基础化学高级总监，领导免疫学和炎症药物化学部、生物物理化学部。他在Wesleyan University 获得化学与哲学学士学位，在Harvard University获得化学硕士、博士学位。
- Joshua S. Boger is the founder of Vertex and has been a director since inception in 1989. He was Chief Executive Officer from 1992 through May 2009. He was Chairman of Board of Directors from 1997 until May 2006 and President from inception until December 2000 and from 2005 through February 2009. He was Chief Scientific Officer from 1989 until May 1992. Prior to founding Vertex in 1989 Dr. Boger held the position of Senior Director of Basic Chemistry at Merck Sharp & Dohme Research Laboratories in Rahway, New Jersey, where he headed both the Department of Medicinal Chemistry of Immunology & Inflammation and the Department of Biophysical Chemistry. Dr. Boger holds a B.A. in chemistry and philosophy from Wesleyan University and M.S. and Ph.D. degrees in chemistry from Harvard University.
高管简历
中英对照 | 中文 | 英文- Kelly Blackburn
Kelly Blackburn自2013年7月起担任临床事务副总裁。Blackburn从2012年9月到2013年7月担任多个公司顾问，包括Agios Pharmaceuticals, Promedior Inc. and aTyr。在此之前，Blackburn从2006年9月到2012年9月担任Vertex Pharmaceuticals Incorporated临床开发运营副总裁。任职期间，她为Kalydeco and Incivek监管NDA的全球运营。Blackburn从2002年9月到2006年8月担任Millennium Pharmaceuticals临床和安全运营主管，负责VELCADE项目，在她任职期间获得认证通过。Blackburn还从2013年7月到2014年12月担任Transforme1（一家新型数据获取技术公司）顾问。Blackburn持有University of New Hampshire生物化学理学学士学位；Quinnipiac College医院管理硕士学位；Quinnipiac College教育学硕士学位。
Kelly Blackburn has served as Vice President, Clinical Affairs since July 2013. Ms. Blackburn served as a consultant from September 2012 to July 2013 to a number of companies, including Agios Pharmaceuticals, a biopharmaceutical company, Promedior Inc. and aTyr. Prior to this, Ms. Blackburn was the Vice President, Clinical Development Operations at Vertex Pharmaceuticals Incorporated, a global biotechnology company, from September 2006 to September 2012. In this role she oversaw the global operations through to NDA for Kalydeco and Incivek. From September 2002 to August 2006 Ms. Blackburn was Director of Clinical and Safety Operations for Millennium Pharmaceuticals where she was responsible for the VELCADE program which was successfully approved during her tenure. Ms. Blackburn has also served as an advisor to Transforme1 a new technology company for data capture, from July 2013 to December 2014. Ms. Blackburn holds a B.S. in biochemistry from University of New Hampshire, an M.H.A. from Quinnipiac College and a M.Ed. from Cambridge College.- Kelly Blackburn自2013年7月起担任临床事务副总裁。Blackburn从2012年9月到2013年7月担任多个公司顾问，包括Agios Pharmaceuticals, Promedior Inc. and aTyr。在此之前，Blackburn从2006年9月到2012年9月担任Vertex Pharmaceuticals Incorporated临床开发运营副总裁。任职期间，她为Kalydeco and Incivek监管NDA的全球运营。Blackburn从2002年9月到2006年8月担任Millennium Pharmaceuticals临床和安全运营主管，负责VELCADE项目，在她任职期间获得认证通过。Blackburn还从2013年7月到2014年12月担任Transforme1（一家新型数据获取技术公司）顾问。Blackburn持有University of New Hampshire生物化学理学学士学位；Quinnipiac College医院管理硕士学位；Quinnipiac College教育学硕士学位。
- Kelly Blackburn has served as Vice President, Clinical Affairs since July 2013. Ms. Blackburn served as a consultant from September 2012 to July 2013 to a number of companies, including Agios Pharmaceuticals, a biopharmaceutical company, Promedior Inc. and aTyr. Prior to this, Ms. Blackburn was the Vice President, Clinical Development Operations at Vertex Pharmaceuticals Incorporated, a global biotechnology company, from September 2006 to September 2012. In this role she oversaw the global operations through to NDA for Kalydeco and Incivek. From September 2002 to August 2006 Ms. Blackburn was Director of Clinical and Safety Operations for Millennium Pharmaceuticals where she was responsible for the VELCADE program which was successfully approved during her tenure. Ms. Blackburn has also served as an advisor to Transforme1 a new technology company for data capture, from July 2013 to December 2014. Ms. Blackburn holds a B.S. in biochemistry from University of New Hampshire, an M.H.A. from Quinnipiac College and a M.Ed. from Cambridge College.
- Mark De Rosch
Mark de Rosch自2021年3月起担任我们的首席运营官。在这个职位上，De Rosch博士负责领导我们的全球运营和监管战略。在加入我们之前，De Rosch博士于2019年9月至2021年3月担任Epizyme, Inc.或Epizyme的首席监管官，并领导了其首个获批产品Tazverik®；Tazemetostat的监管工作。在Epizyme之前，De Rosch博士于2018年4月至2019年9月担任Nightstar Therapeutics或Nightstar（于2019年被Biogen收购）的监管事务和质量保证高级副总裁，在那里他为脉络膜失调症和视网膜色素变性的基因治疗计划制定并实施了全球监管路线图。在加入Nightstar之前，他于2014年8月至2018年2月担任Akebia Therapeutics, Inc.的高级副总裁，负责监管事务，质量保证和化学，制造和控制。De Rosch博士拥有加州大学圣地亚哥分校的无机化学博士学位和硕士学位，以及威斯康星大学帕克赛德分校的化学/生物化学学士学位。
Mark De Rosch has served as Chief Operating Officer since March 2021. In this role, Dr. De Rosch is responsible for leading global operations and regulatory strategy. Dr. De Rosch served as Chief Regulatory Officer of Epizyme, Inc., or Epizyme, from September 2019 to March 2021 and led regulatory efforts for their first approved product, TAZVERIK tazemetostat. Prior to Epizyme, Dr. De Rosch served as Senior Vice President, Regulatory Affairs and Quality Assurance for Nightstar Therapeutics, or Nightstar, (acquired by Biogen in 2019) from April 2018 to September 2019 where he developed and implemented global regulatory roadmaps for their gene therapy programs in choroideremia and retinitis pigmentosa. Prior to Nightstar, he served as Senior Vice President, Regulatory Affairs, Quality Assurance and Chemistry, Manufacturing and Controls at Akebia Therapeutics, Inc. from August 2014 to February 2018. Dr. De Rosch holds a Ph.D. and an M.S. in Inorganic Chemistry from the University of California, San Diego and a B.S. in Chemistry/Biochemistry from the University of Wisconsin-Parkside.- Mark de Rosch自2021年3月起担任我们的首席运营官。在这个职位上，De Rosch博士负责领导我们的全球运营和监管战略。在加入我们之前，De Rosch博士于2019年9月至2021年3月担任Epizyme, Inc.或Epizyme的首席监管官，并领导了其首个获批产品Tazverik®；Tazemetostat的监管工作。在Epizyme之前，De Rosch博士于2018年4月至2019年9月担任Nightstar Therapeutics或Nightstar（于2019年被Biogen收购）的监管事务和质量保证高级副总裁，在那里他为脉络膜失调症和视网膜色素变性的基因治疗计划制定并实施了全球监管路线图。在加入Nightstar之前，他于2014年8月至2018年2月担任Akebia Therapeutics, Inc.的高级副总裁，负责监管事务，质量保证和化学，制造和控制。De Rosch博士拥有加州大学圣地亚哥分校的无机化学博士学位和硕士学位，以及威斯康星大学帕克赛德分校的化学/生物化学学士学位。
- Mark De Rosch has served as Chief Operating Officer since March 2021. In this role, Dr. De Rosch is responsible for leading global operations and regulatory strategy. Dr. De Rosch served as Chief Regulatory Officer of Epizyme, Inc., or Epizyme, from September 2019 to March 2021 and led regulatory efforts for their first approved product, TAZVERIK tazemetostat. Prior to Epizyme, Dr. De Rosch served as Senior Vice President, Regulatory Affairs and Quality Assurance for Nightstar Therapeutics, or Nightstar, (acquired by Biogen in 2019) from April 2018 to September 2019 where he developed and implemented global regulatory roadmaps for their gene therapy programs in choroideremia and retinitis pigmentosa. Prior to Nightstar, he served as Senior Vice President, Regulatory Affairs, Quality Assurance and Chemistry, Manufacturing and Controls at Akebia Therapeutics, Inc. from August 2014 to February 2018. Dr. De Rosch holds a Ph.D. and an M.S. in Inorganic Chemistry from the University of California, San Diego and a B.S. in Chemistry/Biochemistry from the University of Wisconsin-Parkside.
- William Elder
William R.Elder自2020年9月起担任我们的总法律顾问兼公司秘书。在加入Diffusion之前，Elder先生主要担任BillyVonelds，LLC的总裁兼首席执行官，该公司是一家长达一个赛季的日常幻想体育公司，他从2019年4月至2020年9月管理该业务的所有公司，法律和运营方面。从2020年7月到2020年9月，Elder先生还担任Diffusion的兼职顾问。从2011年到2019年2月，Elder先生担任国际律师事务所Dechert LLP的公司和证券助理，在那里，Elder先生的业务主要集中在为上市公司提供有关证券法和监管要求，公司治理事务以及股票和债务市场中的金融交易的咨询。他在宾夕法尼亚大学法学院获得法学博士学位，在维拉诺瓦大学获得金融硕士学位，在塔夫茨大学获得经济学学士学位。
William Elder,has served as the Company's General Counsel & Corporate Secretary since September 2020 and as the Company's Chief Financial Officer since June 2024. Mr. Elder has also served as Principal Financial Officer since March 2024, previously served as Diffusion's Principal Financial Officer from June 2023 to August 2023 and also served as a part-time consultant to Diffusion from July 2020 to September 2020. Prior to joining Diffusion, Mr. Elder principally served as president and chief executive officer of BillyVonElds, LLC, a season-long and daily fantasy sports company, where he managed all financial, legal, and operational aspects of the business from April 2019 to September 2020. From 2011 to February 2019, Mr. Elder served as a corporate and securities associate for Dechert LLP, an international law firm, where Mr. Elder's practice focused primarily on counseling public companies on capital markets transactions, mergers and acquisitions, and corporate governance matters. Prior to joining Dechert LLP, Mr. Elder served as an analyst for Creative Financial Group. He received his J.D. from the University of Pennsylvania Law School, an M.S. in finance from Villanova University, and a B.A. in economics from Tufts University.- William R.Elder自2020年9月起担任我们的总法律顾问兼公司秘书。在加入Diffusion之前，Elder先生主要担任BillyVonelds，LLC的总裁兼首席执行官，该公司是一家长达一个赛季的日常幻想体育公司，他从2019年4月至2020年9月管理该业务的所有公司，法律和运营方面。从2020年7月到2020年9月，Elder先生还担任Diffusion的兼职顾问。从2011年到2019年2月，Elder先生担任国际律师事务所Dechert LLP的公司和证券助理，在那里，Elder先生的业务主要集中在为上市公司提供有关证券法和监管要求，公司治理事务以及股票和债务市场中的金融交易的咨询。他在宾夕法尼亚大学法学院获得法学博士学位，在维拉诺瓦大学获得金融硕士学位，在塔夫茨大学获得经济学学士学位。
- William Elder,has served as the Company's General Counsel & Corporate Secretary since September 2020 and as the Company's Chief Financial Officer since June 2024. Mr. Elder has also served as Principal Financial Officer since March 2024, previously served as Diffusion's Principal Financial Officer from June 2023 to August 2023 and also served as a part-time consultant to Diffusion from July 2020 to September 2020. Prior to joining Diffusion, Mr. Elder principally served as president and chief executive officer of BillyVonElds, LLC, a season-long and daily fantasy sports company, where he managed all financial, legal, and operational aspects of the business from April 2019 to September 2020. From 2011 to February 2019, Mr. Elder served as a corporate and securities associate for Dechert LLP, an international law firm, where Mr. Elder's practice focused primarily on counseling public companies on capital markets transactions, mergers and acquisitions, and corporate governance matters. Prior to joining Dechert LLP, Mr. Elder served as an analyst for Creative Financial Group. He received his J.D. from the University of Pennsylvania Law School, an M.S. in finance from Villanova University, and a B.A. in economics from Tufts University.
- John Alam
John Alam，自2023年8月起担任总裁兼首席执行官和董事。Alam博士是EIP的联合创始人，曾于2018年4月至2023年8月担任EIP总裁兼首席执行官，并担任EIP董事会成员。在此之前，Alam博士自2010年成立以来一直担任EIP的前身实体EIP Pharma，LLC的管理成员。2011年1月至2014年8月，Alam博士在全球制药公司赛诺菲 S.A.（NASDAQ：SNY）担任老龄化疾病治疗领域负责人。从1997年到2008年，他在福泰制药（纳斯达克股票代码：VRTX）担任越来越重要的职务，最近担任首席医疗官和药物开发执行副总裁。1991年至1997年，Alam博士曾在Biogen Inc.（纳斯达克股票代码：BIIB）工作，在那里他领导了Avonex的临床开发，这是一种治疗多发性硬化症的药物。从2014年到2022年，Alam博士担任老龄化研究联盟的董事会成员，该联盟是一个非营利组织，致力于促进创新，以满足美国老年人的医疗保健需求。Alam博士获得了麻省理工学院化学工程学的S.B.和西北大学医学院的医学博士学位。Alam博士在布莱根妇女医院完成了内科住院医师实习，并在Dana-Farber癌症研究所完成了博士后奖学金。
John Alam,has served as President and Chief Executive Officer and as a director since August 2023. Dr. Alam was EIP's co-founder and served as EIP's President and Chief Executive Officer and as a member of EIP's board of directors from April 2018 to August 2023. Prior to that, Dr. Alam served as a managing member of EIP Pharma, LLC, EIP's predecessor entity, from its inception in 2010. From January 2011 to August 2014, Dr. Alam served as therapeutic area head for diseases of aging at Sanofi S.A. (NASDAQ: SNY), a global pharmaceutical company. From 1997 until 2008, he held positions of increasing responsibility at Vertex Pharmaceuticals (NASDAQ: VRTX), most recently as Chief Medical Officer and Executive Vice President, Medicines Development. From 1991 to 1997, Dr. Alam worked at Biogen Inc. (NASDAQ: BIIB), where he led the clinical development of Avonex, a drug that treats multiple sclerosis. From 2014 to 2022, Dr. Alam served as a member of the board of directors of the Alliance for Aging Research, a non-profit organization dedicated to promoting innovation to address the healthcare needs of older Americans. Dr. Alam received an S.B. in chemical engineering from the Massachusetts Institute of Technology and a M.D. from Northwestern University School of Medicine. Dr. Alam completed an internal medicine residency at Brigham and Women's Hospital and a post-doctoral fellowship at Dana-Farber Cancer Institute.- John Alam，自2023年8月起担任总裁兼首席执行官和董事。Alam博士是EIP的联合创始人，曾于2018年4月至2023年8月担任EIP总裁兼首席执行官，并担任EIP董事会成员。在此之前，Alam博士自2010年成立以来一直担任EIP的前身实体EIP Pharma，LLC的管理成员。2011年1月至2014年8月，Alam博士在全球制药公司赛诺菲 S.A.（NASDAQ：SNY）担任老龄化疾病治疗领域负责人。从1997年到2008年，他在福泰制药（纳斯达克股票代码：VRTX）担任越来越重要的职务，最近担任首席医疗官和药物开发执行副总裁。1991年至1997年，Alam博士曾在Biogen Inc.（纳斯达克股票代码：BIIB）工作，在那里他领导了Avonex的临床开发，这是一种治疗多发性硬化症的药物。从2014年到2022年，Alam博士担任老龄化研究联盟的董事会成员，该联盟是一个非营利组织，致力于促进创新，以满足美国老年人的医疗保健需求。Alam博士获得了麻省理工学院化学工程学的S.B.和西北大学医学院的医学博士学位。Alam博士在布莱根妇女医院完成了内科住院医师实习，并在Dana-Farber癌症研究所完成了博士后奖学金。
- John Alam,has served as President and Chief Executive Officer and as a director since August 2023. Dr. Alam was EIP's co-founder and served as EIP's President and Chief Executive Officer and as a member of EIP's board of directors from April 2018 to August 2023. Prior to that, Dr. Alam served as a managing member of EIP Pharma, LLC, EIP's predecessor entity, from its inception in 2010. From January 2011 to August 2014, Dr. Alam served as therapeutic area head for diseases of aging at Sanofi S.A. (NASDAQ: SNY), a global pharmaceutical company. From 1997 until 2008, he held positions of increasing responsibility at Vertex Pharmaceuticals (NASDAQ: VRTX), most recently as Chief Medical Officer and Executive Vice President, Medicines Development. From 1991 to 1997, Dr. Alam worked at Biogen Inc. (NASDAQ: BIIB), where he led the clinical development of Avonex, a drug that treats multiple sclerosis. From 2014 to 2022, Dr. Alam served as a member of the board of directors of the Alliance for Aging Research, a non-profit organization dedicated to promoting innovation to address the healthcare needs of older Americans. Dr. Alam received an S.B. in chemical engineering from the Massachusetts Institute of Technology and a M.D. from Northwestern University School of Medicine. Dr. Alam completed an internal medicine residency at Brigham and Women's Hospital and a post-doctoral fellowship at Dana-Farber Cancer Institute.
- Marco Verwijs
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Matthew Winton
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介